Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Current anti-retroviral treatment (ART) effectively suppresses HIV but does not eliminate the viral reservoir.
• Cessation of ART leads to rapid viral rebound driven by reservoirs in memory CD4+ T cells.
• Eliminating this reservoir is crucial for achieving a functional HIV cure.

Purpose of the Study:

• To review the strategy of repurposing alefacept, an FDA-approved biologic, to target and reduce the HIV reservoir.
• To investigate the potential of alefacept in contributing to a functional HIV cure by depleting CD2-expressing memory CD4+ T cells.

Main Methods:

• Alefacept, a fusion protein targeting the CD2 coreceptor on memory T cells, was initially developed for psoriasis.
• Alefacept induces depletion of CD2-high memory T cells via NK cell-mediated antibody-dependent cell cytotoxicity (ADCC).
• Review of clinical trial data demonstrating alefacept's safety and efficacy in other memory T cell-mediated conditions.

Main Results:

• Alefacept has a proven safety profile from extensive clinical trials in psoriasis patients.
• The drug has been successfully repurposed for other autoimmune diseases involving memory T cells.
• The mechanism of alefacept involves the depletion of CD2-expressing memory T cells, a key component of the HIV reservoir.

Conclusions:

• Alefacept's ability to deplete memory T cells presents a promising strategy for targeting the HIV reservoir.
• Repurposing alefacept offers a novel therapeutic approach for a functional HIV cure.
• Further research and clinical application of alefacept could lead to the elimination of the latent HIV reservoir.